Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Pacira BioSciences, Inc.
  6. News
  7. Summary
    PCRX   US6951271005

PACIRA BIOSCIENCES, INC.

(PCRX)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-03 pm EST
41.86 USD   -2.81%
01/31Wedbush Assumes Pacira BioSciences at Outperform, Cuts Price Target to $60 From $88
MT
01/09Transcript : Pacira BioSciences, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-09-2023 03:00 PM
CI
01/06Needham Adjusts Price Target on Pacira BioSciences to $63 From $66, Maintains Buy Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

RBC Trims Pacira BioSciences' Price Target to $80 From $82, Keeps Outperform Rating

11/04/2022 | 08:20am EST
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about PACIRA BIOSCIENCES, INC.
01/31Wedbush Assumes Pacira BioSciences at Outperform, Cuts Price Target to $60 From $88
MT
01/09Transcript : Pacira BioSciences, Inc. Presents at 41st Annual J.P. Morgan Hea..
CI
01/06Needham Adjusts Price Target on Pacira BioSciences to $63 From $66, Maintains Buy Ratin..
MT
01/06BMO Capital Adjusts Price Target on Pacira BioSciences to $52 From $60, Maintains Marke..
MT
01/05Pacira BioSciences Sees Fiscal 2022 Earnings, Revenue Trailing Analyst Estimates; Share..
MT
01/05Pacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.8 Milli..
GL
01/04Pacira BioSciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
GL
01/04Pacira BioSciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
AQ
2022Pacira BioSciences Reports Monthly Increase in Preliminary Net Product Sales for Novemb..
MT
2022Pacira BioSciences Reports Preliminary Net Product Sales of $57.5 Million for November ..
GL
More news
Analyst Recommendations on PACIRA BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 667 M - -
Net income 2022 43,5 M - -
Net Debt 2022 510 M - -
P/E ratio 2022 50,2x
Yield 2022 -
Capitalization 1 921 M 1 921 M -
EV / Sales 2022 3,64x
EV / Sales 2023 2,87x
Nbr of Employees 697
Free-Float 98,9%
Chart PACIRA BIOSCIENCES, INC.
Duration : Period :
Pacira BioSciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PACIRA BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 41,86 $
Average target price 67,00 $
Spread / Average Target 60,1%
EPS Revisions
Managers and Directors
David M. Stack Chairman & Chief Executive Officer
Charles A. Reinhart Chief Financial Officer
Roy Winston Chief Medical Officer
Charles Anthony Laranjeira Senior Vice President-Technical Operations
Jonathan Slonin Chief Clinical Officer
Sector and Competitors
1st jan.Capi. (M$)
PACIRA BIOSCIENCES, INC.8.42%1 921
JOHNSON & JOHNSON-6.29%430 370
ELI LILLY AND COMPANY-9.61%322 186
NOVO NORDISK A/S0.37%309 611
ROCHE HOLDING AG-2.81%269 030
MERCK & CO., INC.-7.22%260 994